###### Strengths and limitations of this study

-   A large-scale, prospective, real-life study for the management and outcome of patients with cardiorenal syndrome compared with patients with acute heart failure without renal dysfunction.

-   Only two groups were included (ie, patients with or without kidney dysfunction), rather than for each stage of chronic kidney disease although the creatinine clearance cut-off (60 mL/min) is commonly used.

-   Glomerular filtration rate was calculated using three different methods.

-   Glomerular filtration rate estimations were performed by local laboratories for each centre (ie, a real-life situation).

-   There was no clearance monitoring after hospital discharge.

Background {#s1}
==========

Heart failure (HF) has an incidence of approximately 2% in adults in developed countries[@R1] and mainly affects elderly patients, who may have multiple comorbidities. One such comorbidity, impaired renal function, has been shown to be a stronger predictor of mortality than impaired cardiac function[@R2] and can be present in 50% of patients treated for acute HF (AHF).[@R4] The prognostic importance of the association of renal dysfunction (creatinine clearance (CrCl) ≤60 mL/min) and AHF (cardiorenal syndrome (CRS)) has only been demonstrated recently. This represents a complex pathophysiological condition that has been classified into five stages.[@R5] It is worth noting that this is a mechanistic classification and the patients' clinical management must consider the full clinical presentation.

Even moderate degrees of renal insufficiency are independently associated with an increased risk of mortality from any cause in patients with HF.[@R7] As such, CRS can lead to hesitancy among some clinicians to implement appropriate treatments for HF, such as diuretics, due to the effect that these may have to worsen the renal insufficiency. However, additional prospective research is needed and current recommendations are to maintain such treatments in patients with CRS,[@R8] although the emergency physician should make an appropriate risk:benefit assessment for each patient.

In this context, a subanalysis was conducted using real-life data from the Description de la Filière de Soins dans les Syndromes d'Insuffisance Cardiaque Aigue (DeFSSICA study), a large-scale, prospective study that was conducted in patients with suspected dyspnoea of cardiac origin in emergency departments (EDs) throughout France.[@R10] The aim of this subanalysis was to compare the management and outcome of patients with CRS to patients with AHF without renal dysfunction in France using novel real-life data, based on the hypothesis that patients with CRS and AHF would have the same outcome if the management of CRS was based on that for patients with AHF without renal dysfunction.

Methods {#s2}
=======

Study design {#s2a}
------------

This was a prospective, multicentre study in patients presenting with suspected HF dyspnoea in 26 EDs in academic, community and regional hospitals (the DeFSSICA study) for which the rationale and design are reported elsewhere.[@R10] Written information regarding the objectives of the survey was provided to all patients prior to their inclusion according to French law. Each participating physician presented the study to the patient and/or the patient's family. The patient and/or the patient's family could choose for the patient to withdraw from the study at any time. The study did not affect the patient--physician relationship or the patient's care and follow-up.

Patient involvement {#s2b}
-------------------

The research question was based on the prognostic importance of CRS and a need for real-life data on the management and outcome of patients with CRS. Patients were not involved in the design, recruitment and conduct of the study, and there is no plan to disseminate the results specifically to the patients who provided data used in this analysis.

Selection of participants {#s2c}
-------------------------

In the DeFSSICA survey, patients \>18 years of age with dyspnoea compatible with AHF, defined as dyspnoea associated with peripheral oedema and/or pulmonary crackles and/or excessive weight gain and/or use of furosemide, were eligible for inclusion after ED admission and prior to chest X-ray and laboratory tests. Patient enrolment occurred between 16 June 2014 and 7 July 2014.

In this analysis, only patients with known CrCl were included and were divided into those with CrCl ≤60 mL/min, that is, renal dysfunction (group 1) and those with CrCl \>60 mL/min, that is, normal renal function (group 2). Glomerular filtration rate (GFR) was calculated using either the Cockroft-Gault (9 centres), modification of diet in renal disease study (12 centres) or Chronic Kidney Disease (CKD) Epidemiology Collaboration equations (14 centres) (8 centres used two methods and 18 centres used one method).[@R11]

Study assessments {#s2d}
-----------------

Patients' baseline characteristics, medical history, social factors, in-hospital diagnostic tests and treatment, destination after ED discharge, in-hospital mortality and length of stay were recorded by emergency physicians in a case report form, which was structured according to the progress of care. Cardiac sonographic evaluations were performed at the discretion of the emergency physician. Abnormal chest X-ray was defined by the presence of cardiomegaly and/or alveolar oedema and/or interstitial opacity, and/or pleural effusion. The choice of treatment was at the emergency physician's discretion and according to his/her usual practice. A final diagnosis of AHF was made by the emergency physician using a combination of a clinical history, abnormal chest X-ray, elevated brain-type natriuretic peptide (BNP) or BNP prohormone (pro-BNP), and echocardiographic signs.

Although it was not possible to impose any randomisation or blinding since this was an observational study, any potential bias in the study assessments was minimised by the provision of standard instructions to all participating physicians.

Data were entered into a secure database located at the Réseau Cardiologie Urgence (Cardiovascular Emergency Network) Coordination Centre.

Statistical analysis {#s2e}
--------------------

Medians and IQRs are provided for continuous variables, and numbers and percentages for qualitative variables. Comparative analyses were performed using the χ^2^ or Fisher's exact test for binary variables and the Wilcoxon test for analysis of variance for continuous variables.[@R13] The 5% level was used to identify differences between groups that were of statistical significance (p\<0.05). Statistical evaluations were performed using R Statistical Software (V.3.4.1).

Results {#s3}
=======

Patient disposition and prevalence of CRS {#s3a}
-----------------------------------------

A total of 64 281 ED consultations took place during the survey period and 699 patients with dyspnoea of cardiac origin were included in DeFSSICA study. Of these, 537 patients were identified as having AHF, of whom only those with known CrCl (n=507) were included in this analysis.

Patients in group 1 (n=335 (66.1%)) had renal dysfunction (CrCl ≤60 mL/min) and comprised the population with CRS. In this group, 99 patients (29.6%) had severe renal dysfunction (stage 4 or 5: CrCl: \<30 mL/min) and 120 (35.8%) had a known history of chronic renal failure. All patients in group 2 (n=172 (33.9%)) had normal renal function (CrCl \>60 mL/min).

Patient disposition is presented in [figure 1](#F1){ref-type="fig"}.

Baseline characteristics {#s3b}
------------------------

The baseline characteristics of patients in group 1 and group 2 are shown in [table 1](#T1){ref-type="table"}. There was no difference between group 1 and group 2 in age (median (IQR): 84 (88--79) years and 82 (75--88) years; p=0.09) or sex distribution (42.99% male in group 1 and 44.19% male in group 2; p=0.87).

![Patient disposition. DeFSSICA, Description de la Filière de Soins dans les Syndromes d'Insuffisance Cardiaque Aigue; HF, heart failure.](bmjopen-2018-022776f01){#F1}

###### 

Baseline characteristics of patients with confirmed AHF syndrome

  ----------------------------------------------------------------------------------------------------------------
                                                  All patients with AHF\   Group 1\       Group 2\       P value
                                                  (n=507)                  (n=335)        (n=172)        
  ----------------------------------------------- ------------------------ -------------- -------------- ---------
   Age, year                                      83 (77; 88)              84 (78; 89)    82 (75; 88)    0.09

   Men                                            220 (43.39%)             144 (42.99%)   76 (44.19%)    0.87

  Comorbidities                                                                                          

   Hypertension                                   353 (69.63%)             234 (69.85%)   119 (69.19%)   0.79

   Chronic HF                                     271 (53.45%)             189 (56.42%)   82 (47.67%)    \<0.05

   Atrial fibrillation                            223 (43.98%)             151 (45.07%)   72 (41.86%)    0.43

   Coronary heart disease                         150 (29.59%)             98 (29.25%)    52 (30.23%)    1.00

   Diabetes type I                                14 (2.76%)               12 (3.58%)     2 (1.16%)      0.26

   Diabetes type II                               132 (26.04%)             93 (27.76%)    39 (22.67%)    0.20

   Chronic renal failure                          114 (22.49%)             108 (32.24%)   6 (3.49%)      \<0.01

   Chronic respiratory failure                    87 (17.16%)              60 (17.91%)    27 (15.7%)     0.46

   Known valvular disease                         95 (18.74%)              70 (20.9%)     25 (14.53%)    0.07

  Priori medications                                                                                     

   Furosemide                                     295 (58.19%)             204 (60.9%)    91 (52.91%)    \<0.05

   ACEI/ARB                                       225 (44.38%)             153 (45.67%)   72 (41.86%)    0.30

   β-blocker                                      214 (42.21%)             147 (43.88%)   67 (38.95%)    0.20

   Anticoagulant                                  221 (43.59%)             151 (45.07%)   70 (40.7%)     0.24

   Aspirin                                        155 (30.57%)             110 (32.84%)   45 (26.16%)    0.08

   Other antiplatelet                             56 (11.05%)              37 (11.04%)    19 (11.05%)    0.73

   Oral antidiabetic                              66 (13.02%)              47 (14.03%)    19 (11.05%)    0.22

   Insulin                                        68 (13.41%)              52 (15.52%)    16 (9.3%)      0.03

   Amiodarone                                     56 (11.05%)              48 (14.33%)    8 (4.65%)      \<0.01

   Aldosterone antagonist                         38 (7.5%)                26 (7.76%)     12 (6.98%)     0.48

   Digoxin                                        38 (7.5%)                18 (5.37%)     20 (11.63%)    0.10

   Thiazidine                                     32 (6.31%)               21 (6.27%)     11 (6.4%)      0.70

   None                                           28 (5.52%)               14 (4.18%)     14 (8.14%)     0.38

   Unknown                                        13 (2.56%)               7 (2.09%)      6 (3.49%)      1.00

  Prior hospitalisation for HF during past year                                                          

   0                                              287 (56.61%)             180 (53.73%)   107 (62.21%)   0.14

   1                                              130 (25.64%)             83 (24.78%)    47 (27.33%)    0.86

   ≥2                                             62 (12.23%)              52 (15.52%)    10 (5.81%)     \<0.01

   Followed by a cardiologist                     348 (68.64%              242 (72.24%)   106 (61.63%)   0.02

   Residence                                                                                             

   At home                                        423 (83.43%)             287 (85.67%)   136 (79.07%)   0.06

   Retirement institution                         74 (14.6%)               43 (12.84%)    31 (18.02%)    0.18

   Other institution                              8 (1.58%)                4 (1.19%)      4 (2.33%)      0.75

   Self-sufficient                                258 (50.89%)             162 (48.36%)   96 (55.81%)    0.19

  Home assistance                                                                                        

   Housekeeper                                    151 (29.78%)             111 (33.13%)   40 (23.26%)    0.02

   Family support                                 121 (23.87%)             87 (25.97%)    34 (19.77%)    0.10

   Nurse                                          134 (26.43%)             98 (29.25%)    36 (20.93%)    0.04

   Known cognitive impairment                     83 (16.37%)              49 (14.63%)    34 (19.77%)    0.26

   Bedridden                                      45 (8.88%)               25 (7.46%)     20 (11.63%)    0.28
  ----------------------------------------------------------------------------------------------------------------

Data are median (IQR) age or number (%) of patients.

Group 1: patients with CRS; group 2: patients with normal renal function.

ACEI, ACE inhibitor; AHF, acute heart failure; ARB, angiotensin II receptor blocker; CRS, cardiorenal syndrome; HF, heart failure.

As well as the higher incidence of chronic renal failure in group 1, patients with CRS were more likely to have chronic HF (56.42% in group 1 vs 47.67% in group 2; p\<0.05). There was no difference in the incidence of any other comorbidity between groups. Patients in group 1 were more likely than patients in group 2 to receive furosemide (60.9% vs 52.91%; p\<0.05), insulin (15.52% vs 9.3%; p=0.03) and amiodarone (14.33% vs 4.65%; p\<0.01), but there were no other differences between groups for medications. Additionally, patients in group 1 were more likely to have been hospitalised for HF at least twice during the last year (15.52% vs 8.81%; p\<0.01), and to be under the care of a cardiologist (72.24% vs 61.63%; p=0.02). The incidence of patients carrying a defibrillator and of pacemakers (single, dual or triple) are not presented since the sample sizes were small (n=16 and n=17, n=36 and n=6, respectively) and so the data were not considered sufficiently robust. Patients in group 1 were more likely to have a housekeeper (31.13% vs 23.26%; p=0.02) and nurse (29.25% vs 20.93%; p=0.04), but there was no difference between groups regarding family support, known cognitive impairment or the incidence of being bedridden.

Hospitalisation and clinical status {#s3c}
-----------------------------------

Although there were few statistically significant differences between groups in hospitalisation and clinical status parameters ([table 2](#T2){ref-type="table"}), there was a consistent trend towards more congestion in group 1, including higher levels of dyspnoea, more pulmonary infiltrates on chest X-ray, higher BNP and pro-BNP ([table 3](#T3){ref-type="table"} and below).

###### 

Hospitalisation route and clinical status of patients with confirmed AHF syndrome

  --------------------------------------------------------------------------------------------------------
                                   All patients with AHF\   Group 1\         Group 2\            P value
                                   (n=507)                  (n=335)          (n=172)             
  -------------------------------- ------------------------ ---------------- ------------------- ---------
  Means of transport                                                                             

   Personal                        232 (45.76%)             157 (46.87%)     75 (43.6%)          0.50

   Ambulance                       89 (17.55%)              56 (16.72%)      33 (19.19%)         0.63

   Firemen                         55 (10.85%)              34 (10.15%)      21 (12.21%)         0.65

   MICU                            40 (7.89%)               29 (8.66%)       11 (6.4%)           0.41

   Interhospital transfer          6 (1.18%)                5 (1.49%)        1 (0.58%)           0.48

  Clinical signs                                                                                 

   Warm extremities                390 (76.92%)             257 (76.72%)     133 (77.33%)        0.23

   Cold extremities                61 (12.03%)              45 (13.43%)      16 (9.3%)           0.97

   Signs of right heart failure    216 (42.6%)              144 (42.99%)     72 (41.86%)         0.69

   Inspiratory retraction          146 (28.8%)              107 (31.94%)     39 (22.67%)         0.02

   Inability to speak              42 (8.28%)               25 (7.46%)       17 (9.88%)          0.54

  First recorded vital signs                                                                     

   Heart failure, beats/min        85 (71; 102)             85 (72; 102)     85 (72; 104.25)     0.49

   SBP, mm Hg                      140 (121; 160)           140 (121; 160)   140 (124; 162)      0.11

   DBP, mm Hg                      76 (65; 90)              75 (63.5; 89)    78 (67.75; 92.25)   0.03

   SBP \<100 mm Hg                 34 (6.71%)               27 (8.06%)       7 (4.07%)           0.13

   Respiratory rate, breaths/min   25 (20, 30)              26 (20, 30)      24 (20, 29)         0.16

   Pulse oximetry, %               94 (90; 96.25)           94 (90; 97)      94 (89; 96)         0.72

   GCS \<15                        48 (9.47%)               31 (9.25%)       17 (9.88%)          0.94

   Temperature \>37°C              13 (2.56%)               12 (3.58%)       1 (0.58%)           0.37

  Killip status                                                                                  

   1                               128 (25.25%)             76 (22.69%)      52 (30.23%)         0.26

   2                               269 (53.06%)             181 (54.03%)     88 (51.16%)         0.30

   3                               84 (16.57%)              60 (17.91%)      24 (13.95%)         0.11

   Signs of shock                  15 (2.96%)               8 (2.39%)        7 (4.07%)           0.89
  --------------------------------------------------------------------------------------------------------

Data are median (IQR) beats/minute, median (IQR) mm Hg, median (IQR) breaths/minute, median (IQR) % or number (%) of patients.

Group 1: patients with CRS; group 2: patients with normal renal function.

AHF, acute heart failure; CRS, cardiorenal syndrome; DBP, diastolic blood pressure; GCS, Glasgow Coma Scale; MICU, mobile intensive care unit; SBP, systolic blood pressure.

###### 

Biological and diagnosis tests of patients with confirmed AHF syndrome

  ------------------------------------------------------------------------------------------------------------------------
                                      All patients with AHF\   Group 1\                  Group 2\                P value
                                      (n=507)                  (n=335)                   (n=172)                 
  ----------------------------------- ------------------------ ------------------------- ----------------------- ---------
  Biological analysis                                                                                            

   Performed                          507 (100%)               335 (100%)                172 (100%)              

   Sodium, mmol/L                     138 (135; 141)           138 (135; 141)            139 (135; 141)          0.40

   Potassium, mmol/L                  4 (4, 5)                 4 (4, 5)                  4 (4, 5)                0.89

   Creatinine clearance, mL/min       50 (35; 69.05)           40 (29; 49.9)             78.5 (67; 91)           \<0.01

   Creatinine clearance \<30 mL/min   89 (17.55%)              89 (26.57%)               0 (0%)                  \<0.01

   Haemoglobin, g/L                   130 (110, 140)           120 (110, 130)            130 (130, 140)          0.06

   Troponin positive                  271 (53.45%)             195 (58.21%)              76 (44.19%)             \<0.01

   BNP, ng/L                          991 (507.5; 2443.5)      1157.5 (569.25; 2680.5)   534 (291; 1292)         \<0.01

   Pro-BNP, ng/L                      4025 (1729; 8863)        5120 (2520; 12 399.75)    2513 (1146.5; 5376.5)   \<0.01

  ECG                                                                                                            

   Performed                          500 (98.61%)             329 (98.20%)              171 (99.41%)            

   Sinusal                            220 (44%)                145 (43.28%)              75 (43.6%)              0.92

   Atrial fibrillation                213 (42.01)              139 (41.49%)              74 (43.02%)             1.00

   Driven                             44 (8.8%)                33 (9.85%)                11 (6.4%)               0.19

   AVB                                21 (4.14%)               14 (4.18%)                7 (4.07%)               0.86

   LBBB                               86 (17.2%)               64 (19.1%)                22 (12.79%)             \<0.05

   RBBB                               59 (11.8%)               34 (10.15%)               25 (14.53%)             0.43

   Repolarisation disorder            101 (20.2%)              73 (21.79%)               28 (16.28%)             0.09

  Chest X-ray                                                                                                    

   Performed                          481 (94.87%)             318 (94.92%)              163 (94.76%)            

   Normal                             24 (4.73%)               11 (3.28%)                13 (7.56%)              0.20

   Cardiomegaly                       235 (48.86%)             171 (51.04%)              64 (37.21%)             0.01

   Interstitial opacities             284 (59.04%)             202 (60.3%)               82 (47.67%)             0.02

   Alveolar opacities                 108 (22.45%)             64 (19.1%)                44 (25.58%)             0.05
  ------------------------------------------------------------------------------------------------------------------------

Data are median (IQR) mmol/L, median (IQR) mL/min, median (IQR) g/dL, median (IQR) ng/L or number (%) of patients.

Group 1: patients with CRS; group 2: patients with normal renal function.

AHF, acute heart failure; AVB, atrioventricular block; BNP, brain natriuretic peptide; CRS, cardiorenal syndrome; LBBB, left bundle branch block; RBBB, right bundle branch block.

There were no significant differences between groups in their means of transport to the ED (most commonly by personal means (45.76% overall)), Killip status (most patients in each group had a Killip status of 2 (53.06% overall) and signs of cardiogenic shock (2.96% overall).

Early management and diagnosis {#s3d}
------------------------------

At admission, blood samples from all patients underwent biological analysis ([table 3](#T3){ref-type="table"}). As well as the differences between groups for CrCl, significant differences were observed for BNP, which was 2.2-fold higher in group 1 than group 2 (1157.5 ng/L vs 534 ng/L; p\<0.01) and pro-BNP, which was twofold higher in group 1 than group 2 (5120 ng/L vs 2513 ng/L; p\<0.01). Additionally, troponin was more likely to be positive in patients in group 1 than group 2 (58.21% vs 44.19%; p\<0.01). There were no differences between groups for sodium, potassium or haemoglobin.

Most patients underwent under an ECG (98.61% overall) chest X-ray (94.87% overall). Patients in group 1 were more likely than those in group 2 to have left bundle branch block (19.1% vs 12.79%; p\<0.05), cardiomegaly (51.04% vs 37.21%; p=0.01) and interstitial opacities (60.3% vs 47.67%; p=0.02).

Echography was only performed for 82 patients and so the data were not considered sufficiently robust for inclusion in the analysis.

Emergency treatments {#s3e}
--------------------

Patients in group 1 were more likely than group 2 to receive emergency treatment of nitrates (21.19% vs 12.21%; p\<0.01), but there were no group differences in other emergency measures (furosemide, oxygen, anticoagulant, continuous positive airway pressure, non-invasive ventilation, antiarrhythmics, ionotropic agents, tracheal intubation) ([table 4](#T4){ref-type="table"}). Overall 6.31% of patients received no emergency treatment, with no difference between groups.

###### 

Emergency treatment of patients with confirmed AHF syndrome

  --------------------------------------------------------------------------------------
                        All patients with AHF\   Group 1\       Group 2\       P value
                        (n=507)                  (n=335)        (n=172)        
  --------------------- ------------------------ -------------- -------------- ---------
  Furosemide            376 (74.16%)             252 (75.22%)   124 (72.09%)   0.26

  Oxygen                337 (66.47%)             225 (67.16%)   112 (65.12%)   0.43

  Nitrates              92 (18.15%)              71 (21.19%)    21 (12.21%)    0.01

  Anticoagulant         37 (7.3%)                22 (6.57%)     15 (8.72%)     1.00

  CPAP                  8 (1.58%)                6 (1.79%)      2 (1.16%)      0.24

  NIV                   45 (8.88%)               30 (8.96%)     15 (8.72%)     0.58

  Antiarrhythmics       23 (4.54%)               15 (4.48%)     8 (4.65%)      0.60

  Ionotropic agents     3 (0.59%)                3 (0.9%)       0 (0%)         0.11

  Tracheal intubation   1 (0.2%)                 1 (0.3%)       0 (0%)         0.20

  None                  32 (6.31%)               17 (5.07%)     15 (8.72%)     0.58
  --------------------------------------------------------------------------------------

Data are number (%) of patients.

Group 1: patients with CRS; group 2: patients with normal renal function.

AHF, acute heart failure; CPAP, continuous positive airway pressure; CRS, cardiorenal syndrome; NIV, non-invasive ventilation.

Outcomes {#s3f}
--------

Precipitating factors were not determined in 42.21% of cases overall, with no overall difference between groups ([table 5](#T5){ref-type="table"}). The most common determined precipitating factors were an infection (25.25% overall), arrhythmia (15.19% overall) and hypertension (10.65% overall). Diabetes decompensation was considered to be the precipitating factor for AHF in 2.99% of patients in group 1 but none in group 2 (p=0.01). There were no other group differences in precipitating factors.

###### 

Outcomes of patients with confirmed AHF syndrome

  -----------------------------------------------------------------------------------------------------
                                       All patients with AHF\   Group 1\       Group 2\       P value
                                       (n=507)                  (n=335)        (n=172)        
  ------------------------------------ ------------------------ -------------- -------------- ---------
  Precipitating factors                                                                       

   Unknown                             214 (42.21%)             138 (41.19%)   76 (44.19%)    0.82

   Infection                           128 (25.25%)             84 (25.07%)    44 (25.58%)    0.89

   Rhythm disorder                     77 (15.19%)              47 (14.03%)    30 (17.44%)    0.67

   Hypertension                        54 (10.65%)              39 (11.64%)    15 (8.72%)     0.19

   Non-adherence to treatment          30 (5.92%)               17 (5.07%)     13 (7.56%)     0.92

   Acute coronary syndrome             21 (4.14%)               15 (4.48%)     6 (3.49%)      0.32

   Eating disorder                     20 (3.94%)               14 (4.18%)     6 (3.49%)      0.39

   Diabetes decompensation             10 (1.97%)               10 (2.99%)     0 (0%)         0.01

  Discharge destination                                                                       

   Cardiology                          142 (28.01%)             100 (29.85%)   42 (24.42%)    0.33

   Geriatric medicine                  61 (12.03%)              34 (10.15%)    27 (15.7%)     0.06

   Other medical unit                  99 (19.53%)              67 (20%)       32 (18.6%)     0.98

   CICU                                62 (12.23%)              42 (12.54%)    20 (11.63%)    1.00

   Resuscitation unit                  16 (3.16%)               11 (3.28%)     5 (2.91%)      0.98

   ED hospitalisation unit             74 (14.6%)               48 (14.33%)    26 (15.12%)    0.72

   Back home                           26 (5.13%)               14 (4.18%)     12 (6.98%)     0.14

   Other                               24 (4.73%)               18 (5.37%)     6 (3.49%)      0.78

  Destination considered appropriate   382 (75.35%)             246 (73.43%)   136 (79.07%)   0.13

  Outcome                                                                                     

   In-hospital mortality               30 (5.92%)               24 (7.16%)     6 (3.49%)      0.97

   Still hospitalised at 30 days       32 (6.31%)               20 (5.97%)     12 (6.98%)     1.00

  Length of stay, days                 7 (4; 13)                8 (4; 13)      6 (3; 12)      0.03
  -----------------------------------------------------------------------------------------------------

Data are number (%) of patients or median (IQR) days.

Group 1: patients with CRS; group 2: patients with normal renal function.

AHF, acute heart failure; CICU, cardiac intesive care unit; CRS, cardiorenal syndrome; ED, emergency department.

There was no difference between groups in discharge destination (which was most often cardiology (28.01% overall)), and the discharge destination was deemed appropriate for a similar number of patients in each group (75.35% overall).

Neither in-hospital mortality (5.92% overall) nor the percentage of patients still hospitalised at 30 days (6.31% overall) was significantly different between group 1 and group 2. However, the median length of stay was 2 days longer in group 1 than in group 2 (8 days vs 6 days; p=0.03) ([table 5](#T5){ref-type="table"}).

Discussion {#s4}
==========

The DeFSSICA study was a large-scale, prospective, real-life study conducted following the admission of patients with AHF to EDs throughout France. As such, the data are primarily applicable to the French population, although wider extrapolation is possible due to coherences with similar studies in other geographical regions. The overall DeFSSICA study data are presented elsewhere[@R10] and the present subanalysis reports real-life data from subgroups of patients with AHF with or without concomitant renal dysfunction, based on a CrCl threshold of 60 mL/min. The results show that AHF admissions to EDs are often associated with renal impairment, with almost two-thirds of AHF admissions having CrCl ≤60 mL/min. This prevalence is comparable to published data from France,[@R14] Italy,[@R15] Poland,[@R17] Spain,[@R18] Taiwan[@R20] and the USA,[@R21] as well as from pan-European[@R24] and wider international studies.[@R26] In these studies,[@R14] the prevalence of renal impairment on the admission of patients with AHF ranged from 54.5% to 64%, including 12.4% to 27.4% of patients with severe renal insufficiency. Patients with a history of chronic renal failure ranged from 21.4% to 32.5%, which is also comparable to the findings of the DeFSSICA survey. However, it should be noted that impaired cardiac function leads to reduced renal perfusion, which could be in addition to an underlying chronic renal insufficiency. Additionally, increased abdominal pressure at admission that can result from ascites can lead to renal vein compression and reduced GFR at admission, which could also result in elevated serum creatinine. It is likely, therefore, that a proportion of acute kidney injury diagnosed at admission based on serum creatinine could be due to temporary changes in perfusion pressures rather than kidney damage per se; these functional reductions in GFR would be expected to recover once a normal haemodynamic function is restored. While it is therefore important to consider the use of biomarkers to provide a more precise assessment of kidney function than serum creatinine,[@R27] it is also important to note that the evidence supporting the preferential use of novel biomarkers rather than serum creatinine to detect acute kidney injury can be inconsistent and remains an area for further research.[@R29]

The overall baseline characteristics, clinical status, biological and diagnostic tests, emergency treatment, and outcome of the patients included in this subanalysis was similar to the overall population in the DeFSSICA study; however, some differences were observed between patients with AHF with and without renal dysfunction, including a trend towards more congestion in patients with CRS. As would be expected due to reduced kidney excretion,[@R33] and as described elsewhere,[@R34] BNP and pro-BNP levels were higher in patients with CRS than in patients with AHF with normal renal function and the percentage of troponin-positive patients was also higher in the CRS group. These biomarkers probably reflect the congestion status and remain formally recommended for the management of patients with AHF, especially for their prognostic value. The appropriate use of loop diuretics and/or vasodilators[@R38] in the CRS group, as well as in the AHF group without renal dysfunction, may explain in part the similar intrahospital mortality rate in each group and the similar proportion of patients with AHF with and without renal dysfunction who were still in hospital 30 days after ED admission. Importantly, therefore, the prognosis of patients with CRS was not significantly different using loop diuretics and/or nitrates to those without renal dysfunction. As such, it appears that the correct congestive assessment is vital in this complex clinical situation with concomitant failures in two organs.

Recent publications suggest that appropriate, fast-acting decongesting therapies, as recommended by international guidelines, improve the prognosis for patients with AHF as long as such therapies are introduced early, even if renal impairment develops at the same time.[@R8] Furthermore, it appears that renal impairment in patients with AHF does not have an adverse impact on patient prognosis provided that the congestion is improved. Renal function should be assessed according to the level of patient congestion, and so tools for the assessment of congestion such as the BNP or pro-BNP biomarkers,[@R39] lung ultrasound B-lines (38) or the assessment of the dimensions and compliance of the inferior vena cava are vital. Additionally, haemoconcentration monitoring can be useful for monitoring congestion and significantly improves the short-term outcome of patients with AHF[@R40] and several routinely assessed biological parameters, for example, serum protein, albumin, haemoglobin and haematocrit have been proposed as surrogate markers.[@R41] Furthermore, formulae have been developed to indirectly estimate plasma volume using haemoglobin and/or haematocrit data.[@R42] Further research is needed to establish the ability of novel biomarkers such as urinary angiotensinogen,[@R44] neutrophil gelatinase-associated lipocalin,[@R45] kidney injury molecule-1,[@R47] interleukin-18,[@R48] *N*-acetyl-β-d-glucosaminidase,[@R50] cystatine C[@R51] or a combination of some or all of these could also be used to improve clinical decision-making and therapy. The assessment of diuresis and natriuresis, which reflect both glomerular and tubular function, could offer a strategy to achieve decongestion.[@R50] Ferreira *et al* [@R55] and Palazzuoli *et al* [@R56] showed that the lack of a diuretic response is a more important prognostic factor than the use of loop diuretics. This suggests a new diagnostic challenge, that is to assess the patient's response to diuretics.[@R57] However, despite some proposals to define diuretic resistance (eg, persistent congestion despite adequate and escalating doses of diuretic with \>80 mg furosemide/day, amount of sodium excreted as a percentage of filtered load \<0.2%, failure to excrete ≥90 mmol of sodium within 72 hours of a 160 mg oral furosemide dose given two times daily) and the means of evaluation (eg, weight loss per unit of 40 mg furosemide (or equivalent), net fluid loss/mg of loop diuretic (40 mg of furosemide or equivalent) during hospitalisation, natriuretic response to furosemide),[@R61] there is currently no consensus for commonly accepted standards. Additionally, it is important that any alteration of GFR should be interpreted in the context of the deterioration of the clinical situation.

Another alternative therapy in CRS is the use of mineralocorticoid antagonists. These have been associated with an improvement in both congestion[@R62] and mortality in patients with HF,[@R64] although the Aldosterone Targeted Neurohormonal Combined with Natriuresis Therapy in Heart Failure (ATHENA-HF) trial results are less conclusive.[@R66] Combined therapies have also been evaluated, including hypotonic saline serum in combination with diuretic therapy to improve diuresis[@R67] and mannitol in combination with furosemide,[@R61] although their benefit in diuretic-resistant patients is not confirmed. The addition of metolazone to furosemide could be of interest because of its capacity to produce diuresis even in patients with low GFR.[@R69] In a meta-analysis, Wang *et al* showed that tolvaptan, an oral vasopressin V~2~-receptor antagonist, may also represent an alternative therapy in worsening renal function (WRF).[@R71] Several studies have shown that tolvaptan can decrease WRF in patients treated with furosemide.[@R72] Finally, venous ultrafiltration allows controlled hydrosodic depletion by subtracting isotonic fluid, compared with diuretics that allow the subtraction of hypotonic fluid. Other studies suggest that the effectiveness of ultrafiltration is associated with a reduction in inflammatory cytokines.[@R74] These and other approaches in patients with cardiac insufficiency and resistance to diuretics have recently been reviewed.[@R61]

The CRS analysis using data from the DeFSSICA survey has some limitations. First, only two groups have been analysed (ie, patients with or without renal dysfunction), whereas CKD is characterised by five stages.[@R5] However, as noted earlier, this is a mechanistic classification and in the present analysis the use of the CrCl threshold of 60 mL/min, which is commonly used to define renal dysfunction,[@R2] is considered to be satisfactory, especially since the small number of patients would not allow a thorough analysis for five subcategories. However, the pathophysiology of WRF in AHF is complex[@R78] and using a spot measurement of serum creatinine to classify CRS has limitations. This approach does not allow the separation of patients with acute and chronic CRS: in the present study, 35.8% of patients included in the CRS group had a history of chronic renal failure and so may not have suffered any acute change in renal function, whereas patients with acute changes in serum creatinine compared with their own baseline but not fulfilling the \<60 mL/min criterion would not have been included in the CRS group. That said, the presence of renal failure on admission remains strongly associated with a poor prognosis irrespective of the anterior renal status and despite the lack of WRF in the first 5 days.[@R79] While the choice of a CrCl threshold of 30 mL/min could have led to a greater chance of obtaining a significant difference between groups in terms of outcome, we based our analysis on the 60 mL/min cut-off since it is more widely used. Second, since the data used are observational, it was not possible to impose any randomisation or blinding, and the number of patients in each group was not balanced. Third, GFR assessments were performed by local laboratories for each centre, rather than standardised at a single centre, and repeated measures of GFR could have improved their accuracy and comparability. The use of different formulae to evaluate CrCl in a chronic disease state and an acute context without knowledge of the baseline value reflects the real-life situation. While potentially problematic, with the possibility of some incorrect classification of CKD, numerous previous studies of the impact of renal failure in AHF have used a similar approach.[@R2] Finally, it was not possible to subclassify different types of CRS in this analysis since Kidney Disease Improving Global Outcomes data were not collected, although as described earlier the small number of patients would not have allowed a thorough analysis for each subcategory.

Conclusion {#s5}
==========

These real-life data suggested that patients with CRS have the same outcome as patients with AHF without renal dysfunction when the treatment of the former group is modelled on that for the latter group. This finding should not limit the use of loop diuretics and/or vasodilators as long as the patients present congestion as assessed using biomarkers and ultrasound. The use of diuretic treatment should be based on a more rapid diagnosis of congestion and evaluation of an inadequate response to diuretics, allowing the rapid and appropriate implementation of alternative therapies if necessary.
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